Compare TPCS & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TPCS | COCH |
|---|---|---|
| Founded | 1956 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 51.0M |
| IPO Year | 2008 | 2021 |
| Metric | TPCS | COCH |
|---|---|---|
| Price | $5.80 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 59.3K | ★ 83.0K |
| Earning Date | 02-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.38 | 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,644,000.00 | $241,000.00 |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $2.88 | $0.36 |
| 52 Week High | $6.31 | $1.89 |
| Indicator | TPCS | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 51.18 |
| Support Level | $4.41 | $0.63 |
| Resistance Level | $5.69 | $0.73 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 40.34 | 32.65 |
Techprecision Corp manufactures precision, large-scale fabricated and machined metal structural components and systems. The company provides end-to-end services, transforming raw materials into precision finished products through custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation, and testing. It manufactures products in accordance with customers' drawings and specifications while complying with applicable national and international industry codes and standards. Its segments are: Ranor, which generates the majority of revenue, and Stadco, both focused on the manufacture and assembly of components mainly for defense and other precision industrial customers.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.